Additional molecularly targetable biomarker discoveries include BRAF mutation testing for variable tumors like melanoma and craniopharyngioma and anaplastic lymphoma kinase (ALK) inhibitors and epidermal growth factor receptors in various subtypes of lung cancer [32, 33]. The gene discussed is ALK; the disease is craniopharyngioma.